Alzheimer's disease

American  

[ahlts-hahy-merz, alts-, awlts-] / ˈɑlts haɪ mərz, ˈælts-, ˈɔlts- /

Or Alzheimer disease

noun

Pathology.

1. a common form of dementia, believed to be caused by changes in the brain, usually beginning in late middle age, characterized by memory lapses, confusion, emotional instability, and progressive loss of mental ability.

---

Alzheimer's disease British  

/ ˈæltsˌhaɪməz /

noun

1. Often shortened to: Alzheimer's.  a disorder of the brain resulting in a progressive decline in intellectual and physical abilities and eventual dementia

---

Alzheimer's disease Scientific  

/ äls′hī-mərz /

1. A progressive, degenerative disease of the brain, commonly affecting the elderly, and associated with the development of amyloid plaques in the cerebral cortex. It is characterized by confusion, disorientation, memory failure, speech disturbances, and eventual dementia. The cause is unknown. Alzheimer's disease is named for its identifier, German psychiatrist Alois Alzheimer (1864–1915).

---

Alzheimer's disease Cultural  

1. A disease in which mental capacity decreases because of the breakdown of brain cells.

---

Discover More

Alzheimer's disease is a major cause of loss of intellectual function in middle-aged and elderly people.

Etymology

Origin of Alzheimer's disease

Named after Alois Alzheimer (1864–1915), German neurologist, who described it in 1907

Example Sentences

Problems with glutamate signaling have been linked to conditions such as Alzheimer's disease, schizophrenia, autism, epilepsy, and others.

From Science Daily

An international team of more than 35 scientists from some of the world’s leading institutions have published new research showing “proof of principle” that advanced Alzheimer’s disease — often characterized not only by the loss of memory and executive function, but of one’s actual personality — could be “reversible.”

From MarketWatch

“Alzheimer’s disease can be reversed to achieve full neurological recovery — not just prevented or slowed — in animal models,” according to researchers at Case Western Reserve University in Cleveland, whose scientists helped lead the investigation.

From MarketWatch

In 2020 and 2021, whenever healthcare investors weren’t talking about Covid-19 vaccines, new treatments for Alzheimer’s disease were the most pressing topic in the sector.

From Barron's

Eli Lilly is running a closely watched trial called Trailblazer-ALZ-3, testing its approved Alzheimer’s treatment Kisunla in patients who have biological signposts in their brain consistent with Alzheimer’s disease, but have yet to experience any cognitive decline.

From Barron's